ACS Medicinal Chemistry Letters · 2019 · 49 citations · 9 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryPharmacodynamicsHit-to-lead OptimizationLigand-based DesignPhosphoinositide SignalingIn Vivo StudiesKinase InhibitorsMedicinal Chemistry ApplicationsPhosphoinositide 3-Kinase Delta InhibitorsPi3k InhibitorsPi3k SignalingPurine AnaloguesPurine Chemistry
A medicinal chemistry effort focused on identifying a structurally diverse candidate for phosphoinositide 3-kinase delta (PI3Kδ) led to the discovery of clinical candidate INCB050465 (20, parsaclisib). The unique structure of 20 contains a pyrazolopyrimidine hinge-binder in place of a purine motif that is present in other PI3Kδ inhibitors, such as idelalisib (1), duvelisib (2), and INCB040093 (3, dezapelisib). Parsaclisib (20) is a potent and highly selective inhibitor of PI3Kδ with drug-like ADME properties that exhibited an excellent in vivo profile as demonstrated through pharmacokinetic studies in rats, dogs, and monkeys and through pharmacodynamic and efficacy studies in a mouse Pfeiffer xenograft model.
9